Robert Goodwin

Dr. Robert Goodwin is the current CEO at Vibliome Therapeutics. Robert has over 25 years of experience in the pharmaceutical industry. Prior to joining Vibliome, they served as Vice President and Global Program Head at Takeda from October 2012 to July 2017. Before Takeda, they were with Beartooth Therapeutics, Inc. and LigoCyte Pharmaceuticals, Inc., where they served as President and Chief Operating Officer from January 2000 to October 2012. Dr. Goodwin began their career in the pharmaceutical industry at the University of Rochester, where they served as Head of the Technology Transfer Office from January 1994 to December 1998.

Dr. Robert Goodwin received their Doctor of Philosophy in Bioengineering from the University of Utah. Robert also holds a Bachelor's Degree in Bioengineering from University of California, Los Angeles.

Frank Hollinger - VP, Chemoinformatics, James Grenzebach - VP, Operations, and Paul Galatsis - VP, Chemistry report to Robert Goodwin.